fda and tirzepatide approval for Zepbound (tirzepatide) injection, the first only obesity treatment of its kind that activates both GIP and GLP-1 hormone receptors - Eli Lilly New Medication approved by the
Description
Drugmaker Novo Nordisk announces they are expanding access to its weight loss drug WeGovy with a new partnership with Weight Watchers.
Keep easy options available, such as yogurt, eggs, soups, smoothies, or ready-to-drink nutrition shakes
New research indicates that maintaining meaningful weight loss after starting GLP-1-based therapies could play an important role in reducing the risk of multiple obesity-related diseases.
GLP-1 receptor agonists are the most talked-about drug class in medicine right now
